BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V:
Post# of 69
(Total Views: 124)
Posted On: 10/01/2018 5:04:05 PM
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Scientific Findings at New York Conferences
- BriaCell is set to present clinical and scientific data on its findings in biomarker analyses from the clinical trials it has so far conducted; the presentations will take place at the upcoming conferences in New York
- The clinical efficacy data, which will be made public in advance of these conferences, is crucial to BriaCell, because it helps advance the company’s BriaDX diagnostic test solution; BriaDX is used in determining the kind of patients with a high likelihood of responding to advanced breast cancer treatment
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is a clinical-stage biotechnology company based in Berkeley, California. The company is in the process of developing off-the-shelf personalized cancer treatment options, targeting advanced breast cancer patients.
Having seen the unmet need, the company embarked on the development of Bria-IMT and is now testing its immunotherapy, through clinical trials, for commercialization.
At the first of two upcoming conferences, the Fourth International Cancer Immunotherapy Conference, slated to take place September 30-October 3, 2018, BriaCell will be presenting a poster on its whole-cell targeted immunotherapy approach to treating advanced breast cancer. The focus of this poster is on circulating tumor cells and cancer-associated cells as biomarkers of treatment response.
The data to be discussed is drawn from the Phase I/IIa findings in the ongoing clinical trials being conducted by BriaCell. The presentation will include, among other things, potential correlation relationship between circulating tumor cells and tumor response to the treatment.
Part of the findings already shows signs of tumor regression, as seen in large tumor-associated cells in patients. These findings go a long way in validating the application of Bria-IMT and in advancing the BriaDX diagnostic test.
Over 50 leaders in the oncology field are expected to make presentations at this conference. Areas of discussion include but are not limited to T cell regulation and their response to cancer, maintenance of immune balance, the convergence of immunotherapy and technology.
The second conference, The MicroCap Conference, will take place on October 1-2, 2018. This is an investor presentation event at which BriaCell will present its key achievements so far, especially the progress on Phase I/IIa, safety and efficacy data from the trials and any discoveries it has made on tumor shrinkage.
The MicroCap Conference brings together investors whose current and target portfolio is in microcap stocks. Here, participants get to interact with one another and, more so, the management teams of companies.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BriaCell is set to present clinical and scientific data on its findings in biomarker analyses from the clinical trials it has so far conducted; the presentations will take place at the upcoming conferences in New York
- The clinical efficacy data, which will be made public in advance of these conferences, is crucial to BriaCell, because it helps advance the company’s BriaDX diagnostic test solution; BriaDX is used in determining the kind of patients with a high likelihood of responding to advanced breast cancer treatment
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is a clinical-stage biotechnology company based in Berkeley, California. The company is in the process of developing off-the-shelf personalized cancer treatment options, targeting advanced breast cancer patients.
Having seen the unmet need, the company embarked on the development of Bria-IMT and is now testing its immunotherapy, through clinical trials, for commercialization.
At the first of two upcoming conferences, the Fourth International Cancer Immunotherapy Conference, slated to take place September 30-October 3, 2018, BriaCell will be presenting a poster on its whole-cell targeted immunotherapy approach to treating advanced breast cancer. The focus of this poster is on circulating tumor cells and cancer-associated cells as biomarkers of treatment response.
The data to be discussed is drawn from the Phase I/IIa findings in the ongoing clinical trials being conducted by BriaCell. The presentation will include, among other things, potential correlation relationship between circulating tumor cells and tumor response to the treatment.
Part of the findings already shows signs of tumor regression, as seen in large tumor-associated cells in patients. These findings go a long way in validating the application of Bria-IMT and in advancing the BriaDX diagnostic test.
Over 50 leaders in the oncology field are expected to make presentations at this conference. Areas of discussion include but are not limited to T cell regulation and their response to cancer, maintenance of immune balance, the convergence of immunotherapy and technology.
The second conference, The MicroCap Conference, will take place on October 1-2, 2018. This is an investor presentation event at which BriaCell will present its key achievements so far, especially the progress on Phase I/IIa, safety and efficacy data from the trials and any discoveries it has made on tumor shrinkage.
The MicroCap Conference brings together investors whose current and target portfolio is in microcap stocks. Here, participants get to interact with one another and, more so, the management teams of companies.
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)